中文摘要：

目的初步探讨儿童成熟B细胞非霍奇金淋巴瘤（B—NHL）中BCL-2、BCL-6蛋白表达及其临床病理意义。方法收集1999—2011年复旦大学附属儿科医院血液科收治的92例初治儿童B—NHL资料，包括伯基特淋巴瘤（burkitl lymphoma，BL）53例，弥漫大B细胞性淋巴瘤（DLBCL）38例，以及介于BL与DLBCL之间未能分类的B细胞淋巴瘤（BL／DLBCL）1例。92例患儿年龄≤16岁。所有病例均经过2家三级甲等医院病理科诊断。通过免疫组织化学技术检测儿童B．NHL中BCL-2、BCL．6蛋白表达情况。结果（1）92例儿童B．NHL中47例进行BCL-2蛋白检测，BCL．2表达阳性率在BL和DLBCL中分别为9．7％（3／31）和33．3％（5／15），差异具有统计学意义（P=0．047）。BCL-2蛋白表达与性别、临床分期及预后无相关性（P〉0．05）。（2）31例儿童B—NHL进行BCL-6蛋白检测，BCL-6表达阳性组与阴性组2年EFS分别为83．3％和45．5％，差异有统计学意义（P=0．019）；在临床分期为Ⅲ-Ⅳ期儿童B-NHL中，BCL-6阳性组与阴性组的2年EFS分别为80％和40％，2组差异具有统计学意义（P=0．023）。结论儿童B．NHL中BCL-2蛋白表达与病理类型有关，BL中BCL-2蛋白一般表达阴性，可用于BL与DLBCL之间的鉴别；儿童B—NHL中BCL-6表达阳性的患儿预后较好，提示BCL-6可能是B-NHL的预后因素之一。

英文摘要：

Objective The study was designed to investigate the protein expression of BCL-2 and BCL-6 in children with B-NHL and its clinic-pathological significance. Method Between July 1999 and October 2011,92 untreated patients （age 16 years or less） with newly diagnosed B-NHL （including BL, DLBCL and BL/DLBCL） were enrolled. We use the immunohistochemical technique （Envision TM） to detect BCL-2, BCL-6 protein expression levels. The expression of BCL-2 and BCL-6 and its association with clinic-pathological features and prognosis were analyzed. Results BCL-2 protein expression was performed in 47 B-NHL, the rate of positivity in BL and DLBCL were 9.7% （3/31） and 33.3% （5/15）, respectively. There was significant difference between them （P =0. 047）. However, there was no association between the expression of BCL-2 and gender, stage and prognosis （P 〉 0.05 ）. BCL-6protein expression was performed in 31 B-NHL, The 2-year EFS was 83.3% for children with BCL-6 protein expression, the other was 45.5%, there was significant differenee between them （P = 0. 019）. Children with positive BCL-6 protein expression had better prognosis. Conclusion BCL-2 protein expression was useful for distinguish BL from DLBCL and BCL-6 protein expression is a prognosis factor of B-NHL.